Roivant Sciences (ROIV) Revenue (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Revenue came in at $5.7 million in Q4 2025, down 73.28% YoY from $21.5 million in Q4 2024, and up 265.37% on a QoQ basis from $1.6 million in Q3 2025.
Roivant Sciences (ROIV) Revenue (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Revenue data on file, last reported at $5.7 million in Q4 2025.
- Quarterly Revenue fell 73.28% year-over-year to $5.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $31.0 million (down 46.28% YoY) and the FY2026 annual result came in at $8.3 million, down 71.57% from the prior year.
- Revenue climbed to $5.7 million in Q4 2025, from $1.6 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $46.1 million in Q4 2021 to a low of $1.6 million in Q3 2025.
- A 5-year average of $14.1 million and a median of $8.0 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2021 — Revenue surged 957.22% — and 2025, when it slumped 73.28%.
- Tracing ROIV's Revenue over 5 years: stood at $46.1 million in 2021, then declined by 26.4% to $33.9 million in 2022, then sank by 30.12% to $23.7 million in 2023, then slipped by 9.33% to $21.5 million in 2024, then tumbled by 73.28% to $5.7 million in 2025.
- The last three Revenue figures came in at $5.7 million (Q4 2025), $1.6 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.44 Mn |
| Dec 31, 2025 | 5.74 Mn |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Dec 31, 2024 | 21.48 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 7.99 Mn |
| Dec 31, 2023 | 23.69 Mn |
| Sep 30, 2023 | 3.65 Mn |
| Jun 30, 2023 | 21.62 Mn |
| Dec 31, 2022 | 33.90 Mn |
| Sep 30, 2022 | 12.53 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Dec 31, 2021 | 46.06 Mn |
| Sep 30, 2021 | 13.99 Mn |
| Jun 30, 2021 | 7.74 Mn |
| Dec 31, 2020 | 5.75 Mn |
| Sep 30, 2020 | 1.32 Mn |
| Jun 30, 2020 | 1.58 Mn |